Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from January 27 to January 31, 2025.
Earlier, the company had received ‘A-’ leadership rating from CDP for its outstanding performance in climate change and water security. This rating reflects Lupin's leadership in environmental transparency and performance and underscores the strategic and systematic efforts in its sustainability journey.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
